Cirmtuzumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | ROR1 |
| Clinical data | |
| Other names | UC-961 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Cirmtuzumab (also UC-961) is an anti-ROR1 humanised monoclonal antibody.
It is an experimental drug in early-stage clinical trials for various cancers including chronic lymphocytic leukemia (CLL).